Roche investor science event from ADA 2010

Phase III data on RG1583(taspoglutide) GLP-1 analogue and overall update on Roche´s franchise in diabetes & metabolism

Monday, 28 June 2010, Orlando, USA

Event to present and discuss new phase III data and results on RG1583(taspoglutide) GLP-1 analogue presented during the 2010 ADA (American Diabetes Association) 70th Scientific Sessions. Further, Roche will provided an overall update on its franchise in diabetes and metabolism.

Webcast Replay

Download mp3 file

More Information


Guide to Roche at ADA 2010

Presentation Slides